Clinical Trial Search

Primary: Area Under The Concentration-Time Curve (AUC) From The Time of Dosing Extrapolated to Time Infinity (AUCinf) For Mirabegron — 81.8; 143; 263; 429 Hour*nanogram per…

Primary: IBS Symptom Severity Score at 12 Weeks — 184.7 score on a scale

Primary: Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 24 Hours Postsurgery (AUC0-24). — 124.51; 136.17…

Primary: Change From Baseline in Conners' Adult ADHD Rating Scales-Observer: Screening Version (CAARS-O:SV) 18-item ADHD Symptoms Total Score at Day 56 — 40.71; 41.59; 40.51…

Primary: Number of Participants With Postoperative Vomiting Between 0 to 2 Hours — 11; 5 Participants

Primary: US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue Therapy — 10.30; 10.31; 0.39…

Primary: Percent of Participants With Visit or Procedure With Provider — 45; 64; 63; 176 Participants

Primary: Phase I: Maximum Tolerated Dose (MTD) / Recommended Phase II Dose (RP2D) — 100 million plaque forming units per mL

Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) — 1; 2; 0; 2 Participants

Primary: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL) — 14.4; 6.54 hr*μM

Primary: Program Satisfaction Ratings — 7.6; 8.3 units on a scale

Primary: Number of Patients With Drug-related Treatment-emergent Adverse Events (TEAEs) — 3; 1; 1; 11 Participants

Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) — 18; 26 Participants

Primary: Number of Participants With 6-Month Progression Free Survival (PFS) — 8; 25; 14 Participants

Primary: Number of Participants With Clinical Success at 1 to 6 Months Post-Therapy as Assessed by Imaging — 57 Participants